glp-1 adoption Obesity Market GLP-1 Survey: 75% of Users

Tirzepatide for Metabolic DysfunctionAssociated Steatohepatitis with Liver Fibrosis

June 2025 On June 6, 2025, the European Medicines Agencys (EMA) safety committee concluded that Novo Nordisks semaglutide-containing drugsincluding the popular weight-loss drug Wegovy and diabetes treatments Ozempic and Rybelsusmay cause rare but serious cases of non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and painless vision loss in one eye due to optic nerve damage

Reduced Inflammation: Many patients notice less swelling in hands and feet or fewer puffy dayssmall clues that internal, vessel-damaging inflammation is diminishing

Elsdleges funkcii a kvetkezk: A hipoglikmia megelzse: A glkagon a mjat glkz felszabadtsra serkenti, gy megakadlyozza a veszlyesen alacsony vrcukorszintet

GLP-1 drugs may lower risk of some cancers spreading, study suggests Weight-loss and diabetes drugs such as Ozempic, Wegovy and Zepbound may do more than help patients manage blood sugar and obesity, according to new research led by the Cleveland Clinic